z-logo
open-access-imgOpen Access
Research Advances in Antitumor Mechanism of Evodiamine
Author(s) -
Luning Li,
Cunxin Zhang,
Chen Huang,
Xinchen Tian,
Wenxue Sun,
Shulong Jiang
Publication year - 2022
Publication title -
journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.436
H-Index - 50
eISSN - 2090-9071
pISSN - 2090-9063
DOI - 10.1155/2022/2784257
Subject(s) - evodiamine , chemistry , protein kinase b , autophagy , pi3k/akt/mtor pathway , pharmacology , apoptosis , wnt signaling pathway , cell cycle , cancer research , signal transduction , biochemistry , medicine , chromatography
Evodiamine is a natural alkaloid extracted from Fructus Evodia. This bioactive alkaloid has been reported to have a wide range of biological activities, including anti-injury, antiobesity, vasodilator, and anti-inflammatory effects. In recent years, it has been found that evodiamine has tumor-suppressive effects on a variety of tumors. There is growing evidence that evodiamine can inhibit the rapid proliferation of tumor cells, induce cell cycle arrest at a certain phase, increase the incidence of apoptosis, promote autophagy, inhibit microangiogenesis and migration, and regulate immunotherapy. Evodiamine can inhibit Wnt/β-catenin, mTOR, NF-κB, PI3K/AKT, JAK-STAT, and other signaling pathways in various cancer cells, and it can significantly downregulate the expression of many tumor markers, such as VEGF and COX-2. These facts partially explain the antitumor mechanism of evodiamine. In this article, the antitumor mechanism of evodiamine was reviewed to provide the basis for its clinical application and therapeutic development in the future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom